Clinical Scorecard: ALS Trial Tests Celecoxib–Ciprofloxacin Combination
At a Glance
| Category | Detail |
|---|---|
| Condition | Amyotrophic Lateral Sclerosis (ALS) |
| Key Mechanisms | Combination of celecoxib and ciprofloxacin (PrimeC) potentially modifies disease progression. |
| Target Population | Patients aged 18 to 75 years with definite or probable ALS within 30 months of symptom onset. |
| Care Setting | Phase 2b randomized clinical trial across 4 centers. |
Key Highlights
- PrimeC demonstrated a safety profile comparable to placebo.
- Numerically slower decline in ALSFRS-R scores with PrimeC at 6 and 18 months.
- No treatment-related deaths or life-threatening events reported.
- Earlier initiation of PrimeC associated with fewer ALS-related complications.
- Biomarker changes observed, including downregulation of microRNAs associated with ALS severity.
Guideline-Based Recommendations
Diagnosis
- Patients should be diagnosed with definite or probable ALS based on clinical criteria.
Management
- Consider PrimeC as a potential disease-modifying therapy in further studies.
Monitoring & Follow-up
- Monitor ALSFRS-R scores and adverse events during treatment.
Risks
- Adverse events occurred in 67% of patients receiving PrimeC, with drug-related events more frequent but mostly mild to moderate.
Patient & Prescribing Data
68 patients enrolled in the trial.
Most patients were receiving riluzole; PrimeC showed a trend towards improved survival and fewer complications.
Clinical Best Practices
- Conduct further studies to validate the efficacy of PrimeC in ALS.
- Evaluate biomarker changes alongside clinical outcomes.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
